Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species

CCT241736 is a dual fms-like tyrosine kinase 3 (FLT3)/Aurora kinase inhibitor in development for the treatment of acute myeloid leukaemia. The successful development of any new drug relies on adequate safety testing including preclinical toxicology studies. Selection of an appropriate preclinical sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Francesca L., Shepherd, Sam, Hayes, Angela, Liu, Manjuan, Grira, Katia, Mok, Yi, Atrash, Butrus, Faisal, Amir, Bavetsias, Vassilios, Linardopoulos, Spiros, Blagg, Julian, Raynaud, Florence I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science B.V 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892276/
https://www.ncbi.nlm.nih.gov/pubmed/30953752
http://dx.doi.org/10.1016/j.ejps.2019.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892276/
https://www.ncbi.nlm.nih.gov/pubmed/30953752
http://dx.doi.org/10.1016/j.ejps.2019.04.004

Ejemplares similares